Exact Sciences (EXAS) reported a Q3 loss late Tuesday of $0.21 per diluted share, compared with breakeven a year earlier.
Analysts polled by Capital IQ expected a loss of $0.18.
Revenue for the quarter that ended Sept. 30 was $708.7 million, up from $628.3 million a year earlier.
Analysts surveyed by Capital IQ expected $717 million.
The company expects full-year 2024 revenue of $2.73 billion to $2.75 billion, compared with its prior projections of $2.81 billion to $2.85 billion. Analysts polled by Capital IQ expect $2.83 billion.
Shares of Exact Sciences traded 28% lower in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.